Kala Bio (KALA) Other financing activities (2017 - 2025)
Kala Bio (KALA) posted Other financing activities of $60000.0 for Q3 2025, up 361.54% sequentially from $13000.0 in Q1 2025, and up 7.14% YoY from $56000.0 in Q3 2024.
Kala Bio (KALA) Other financing activities (2017 - 2025) Analysis & Trends
Kala Bio has reported Other financing activities for 9 years, with the latest figure at $60000.0 in Q3 2025.
- Quarterly Other financing activities rose 7.14% year-over-year to $60000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $73000.0 (down 5.19% YoY) and the FY2025 annual result came in at $73000.0, down 5.19% from the prior year.
- Other financing activities advanced to $60000.0 in Q3 2025 per KALA's latest filing, from $13000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $906000.0 in Q3 2021 and troughed at $6000.0 in Q1 2023.
- A 5-year average of $189272.7 and a median of $60000.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2024: Other financing activities slumped 96.32% in 2023, then soared 250.0% in 2024.
- Over 5 years, Other financing activities stood at $906000.0 in 2021, then slumped by 84.77% to $138000.0 in 2022, then slumped by 71.01% to $40000.0 in 2023, then jumped by 40.0% to $56000.0 in 2024, then increased by 7.14% to $60000.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $60000.0, $13000.0, and $56000.0 for Q3 2025, Q1 2025, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 60,000.00 |
| Sep 30, 2025 | 60,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Mar 31, 2022 | 163,000.00 |
| Mar 31, 2022 | 163,000.00 |
| Sep 30, 2021 | 906,000.00 |
| Sep 30, 2021 | 906,000.00 |
| Jun 30, 2021 | 64,000.00 |
| Jun 30, 2021 | 64,000.00 |